BioMarin Pharmaceutical
BMRN
#1907
Rank
โ‚น921.62 B
Marketcap
โ‚น4,797
Share price
-0.78%
Change (1 day)
-14.38%
Change (1 year)

Revenue for BioMarin Pharmaceutical (BMRN)

Revenue in 2025 (TTM): โ‚น267.49 Billion

According to BioMarin Pharmaceutical's latest financial reports the company's current revenue (TTM ) is โ‚น277.95 Billion. In 2024 the company made a revenue of โ‚น244.82 Billion an increase over the revenue in the year 2023 that were of โ‚น201.39 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for BioMarin Pharmaceutical from 1999 to 2025

Annual revenue

Year Revenue Change
2025 (TTM) โ‚น267.49 B9.26%
2024 โ‚น244.82 B21.56%
2023 โ‚น201.39 B16.11%
2022 โ‚น173.44 B26.22%
2021 โ‚น137.42 B1%
2020 โ‚น136.06 B11.97%
2019 โ‚น121.51 B16.54%
2018 โ‚น104.26 B24.31%
2017 โ‚น83.87 B10.52%
2016 โ‚น75.89 B28.34%
2015 โ‚น59.13 B24.29%
2014 โ‚น47.58 B40.42%
2013 โ‚น33.88 B23.6%
2012 โ‚น27.41 B17.42%
2011 โ‚น23.34 B38.48%
2010 โ‚น16.86 B11.93%
2009 โ‚น15.06 B5.71%
2008 โ‚น14.25 B198.67%
2007 โ‚น4.77 B27.94%
2006 โ‚น3.72 B222.88%
2005 โ‚น1.15 B
2002 โ‚น0.66 B33.82%
2001 โ‚น0.49 B-13.3%
2000 โ‚น0.57 B89.58%
1999 โ‚น0.30 B

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
Ultragenyx Pharmaceutical
RARE
โ‚น56.65 B-79.62%๐Ÿ‡บ๐Ÿ‡ธ USA
Sangamo Therapeutics
SGMO
โ‚น2.95 B-98.94%๐Ÿ‡บ๐Ÿ‡ธ USA
Esperion Therapeutics
ESPR
โ‚น27.29 B-90.18%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
โ‚น4.269 T 1,436.04%๐Ÿ‡ซ๐Ÿ‡ท France
Amicus Therapeutics
FOLD
โ‚น53.78 B-80.65%๐Ÿ‡บ๐Ÿ‡ธ USA
Catalyst Pharmaceuticals
CPRX
โ‚น51.94 B-81.31%๐Ÿ‡บ๐Ÿ‡ธ USA